Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Orphazyme A/S stock

Learn how to easily invest in Orphazyme A/S stock.

Orphazyme A/S is a biotechnology business based in the US. Orphazyme A/S shares (ORPH) are listed on the NASDAQ and all prices are listed in US Dollars. Orphazyme A/S employs 180 staff and has a trailing 12-month revenue of around $13.2 million.

How to buy Orphazyme A/S stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ORPH. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Orphazyme A/S stock price (NASDAQ: ORPH)

Use our graph to track the performance of ORPH stocks over time.

Orphazyme A/S shares at a glance

Information last updated 2022-06-26.
Latest market close$0.34
52-week range$0.30 - $15.40
50-day moving average $1.28
200-day moving average $3.31
Wall St. target price$1.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.83

Buy Orphazyme A/S stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Diversify your portfolio by trading stocks, ETFs, T-Bills, crypto, rare collectibles and more.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Orphazyme A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Orphazyme A/S price performance over time

Historical closes compared with the close of $0.3379 from 2022-04-27

1 week (2023-03-09) N/A
1 month (2023-02-16) N/A
3 months (2022-12-16) N/A
6 months (2022-09-16) N/A
1 year (2022-03-18) -61.60%
2 years (2021-03-19) -97.26%
3 years (2020-03-16) N/A
5 years (2018-03-16) N/A

Orphazyme A/S financials

Revenue TTM $13.2 million
Gross profit TTM $0
Return on assets TTM -88.16%
Return on equity TTM -251.34%
Profit margin 0%
Book value $4.77
Market capitalisation $37.3 million

TTM: trailing 12 months

Orphazyme A/S share dividends

We're not expecting Orphazyme A/S to pay a dividend over the next 12 months.

Orphazyme A/S share price volatility

Over the last 12 months, Orphazyme A/S's shares have ranged in value from as little as $0.3 up to $15.4. A popular way to gauge a stock's volatility is its "beta".

ORPH.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orphazyme A/S's is 0.8023. This would suggest that Orphazyme A/S's shares are less volatile than average (for this exchange).

To put Orphazyme A/S's beta into context you can compare it against those of similar companies.

Orphazyme A/S overview

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. .

Frequently asked questions

What percentage of Orphazyme A/S is owned by institutions?
Currently 3.802% of Orphazyme A/S shares are held by institutions.
How many people work for Orphazyme A/S?
Latest data suggests 180 work at Orphazyme A/S.
When does the fiscal year end for Orphazyme A/S?
Orphazyme A/S's fiscal year ends in December.
Where is Orphazyme A/S based?
Orphazyme A/S's address is: Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
What is Orphazyme A/S's ISIN number?
Orphazyme A/S's international securities identification number is: US6873051022
What is Orphazyme A/S's CUSIP number?
Orphazyme A/S's Committee on Uniform Securities Identification Procedures number is: 687303107

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site